摘要
卵巢癌是女性生殖系统中常见的恶性肿瘤,早期发现卵巢癌可明显改善预后,而临床实施有效的早期筛查是实现这一目标的关键。随着研究的进展,人附睾分泌蛋白4作为一种新型的血清肿瘤标志物,与CA125联合应用在卵巢癌的早期诊断、鉴别诊断以及对盆腔包块预测卵巢癌风险方面均具有很好的临床价值,并有望在早期筛查方面做出贡献。
Ovarian cancer is one of the common malignant tumor in female reproductive system, early detection of ovarian cancer can significantly improve the prognosis, and effective early screening is the key to achieve this goal. With the progress of the study, human epididymis secretory protein 4 （HE4） was known as a new serum tumor marker. The measurement of HFA combined CA125 has a good clinical value in early diagnosis of ovarian cancer, can discriminate ovarian endometriosis cysts from ovarian cancer and predict high. risk of ovarian cancer from pelvic mass women effectively. And then it is expected to make contributions to effective early screening.
出处
《中国实用妇科与产科杂志》
CAS
CSCD
北大核心
2010年第9期664-666,共3页
Chinese Journal of Practical Gynecology and Obstetrics
